A Phase 1, Open-label, Randomized 4-period Crossover Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Subjects
Latest Information Update: 15 Dec 2020
At a glance
- Drugs Mitapivat (Primary) ; Mitapivat
- Indications Inborn error metabolic disorders; Sickle cell anaemia; Thalassaemia
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
Most Recent Events
- 09 Dec 2020 Status changed from recruiting to completed.
- 06 Oct 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 06 Oct 2020 Planned primary completion date changed from 27 Oct 2020 to 1 Dec 2020.